Loading...
Loading...
Bristol-Myers
Squibb Company
BMY today presented extended follow-up
data and a pre-specified interim overall survival (OS) analysis of Empliciti
in combination with Revlimid® (lenalidomide) and
dexamethasone (ERd) in patients with relapsed or refractory multiple
myeloma from ELOQUENT-2. The follow-up data demonstrated that Empliciti
in combination with Rd had an improvement in progression-free
survival (PFS) with a hazard ratio (HR) of 0.73 (95% CI: 0.60, 0.89;
p=0.0014) versus Rd alone. This result was consistent with the
improvement in PFS that was observed at the time of the primary analysis
(HR 0.70 [95% CI: 0.57, 0.85; p = 0.0004]).
The Empliciti combination delayed the need for subsequent myeloma
therapy by
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in